Blog

Did you foresee this £12M cost increase coming?

October sees World Mental Health Day marked and recognised across the globe. The overall objective of the day is to raise awareness of mental health issues and mobilise efforts in support of better mental health. This year’s focus? Mental health in the workplace.

Globally, the WHO reports, “more than 300 million people suffer from depression, the leading cause of disability. More than 260 million are living with anxiety disorders. Many of these people live with both.

The rising costs of mental health disorders

A recent WHO-led study estimates that depression and anxiety disorders cost the global economy US$ 1 trillion each year in lost productivity.” That’s no small sum.

The Guardian reports that 2016 saw the NHS prescribing “a record number of antidepressants, fuelling an upward trend that has seen the number of pills given to patients more than double over the last decade.” (The Guardian)

To demonstrate this, our analysis of the current tariff increase – due to temporary supply issues – of the generic antipsychotic drug Quetiapine (IR) in the UK, shows just how volatile the NHS’s bill for mental health can be.

Quetiapine (IR) in the UK

At-a-glance MarketView analytics

Our interrogative analytics of NHS GP Prescribing Data reveals that the monthly cost to the NHS of Quetiapine (IR)s has risen by over £12M per month in June and July. This ‘temporary’ price concession is still in place now, so the 5 months to October will result in a £50M+ extraordinary cost to the NHS, from just one drug. To put this in context the cost of protecting the whole country from flu with the ‘flu jab’ – costs the NHS around £100M per year.

Inspiremed’s rapid-fire analysis provides valuable insights from NHS and IMS prescription data at the touch of a button. And presents findings in clear easy-to-analyse visualisation dashboards like the one we picture here.

Drill down to key data sets, remove the complexities of data analysis and drive effective sales and marketing activities with real time data.

Book my demonstration

We are working in an ever evolving industry where data increasingly drives marketing and sales activity. I believe RX Analyser is the most comprehensive analytics tool available for prescription data analysis. I can already see other business areas (within my company) that could really benefit.

Sales and Marketing Manager, Leading Healthcare Company, 2016

Obviously I wouldn’t recommend Rx Analyser to our direct competitors as I believe the level of insight provided really gives us an edge.

Sales and Marketing Manager, Leading Healthcare Company, 2016

My favourite feature? The market share data and territory growth or decline. The RXA tool really allows a company to fine tune their sales strategies and focus on the more profitable accounts. It allows you to target accounts for quick wins and get a good picture of what your competitor’s focuses and successes are.

National Sales Manager, UK Pharmaceutical Company

Analyser makes drilling down to the information I need to make key marketing decisions simpler and more targeted. Rx Analyser is both functional and elegant and is backed up by the can-do attitude of the Inspiremed team.

Group Product Manager, Leading Pharmaceutical Company

Benefits? The range of views of the data allows for easier business planning. The data being as up to date as possible enables swift response to market changes. And the ease of changing hierarchy allows for easy management reporting and oversight.

National Sales Manager, UK Pharmaceutical Company

I use the data from RXA Budget Impact Model daily. It is the core of everything we do! I cannot recommend the model more. It has had a substantial impact on our business across the board and I would not be without it.

Country Manager UK, Leading Diagnostics Company

Sign up for added insights